Mackay Shields LLC acquired a new stake in Baxter International Inc (NYSE:BAX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 200,240 shares of the medical instruments supplier’s stock, valued at approximately $13,180,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Gantzert Investment Co. LLC ADV acquired a new stake in shares of Baxter International during the fourth quarter worth $25,000. Parisi Gray Wealth Management acquired a new stake in shares of Baxter International during the fourth quarter worth $26,000. Baldwin Brothers Inc. MA boosted its holdings in shares of Baxter International by 904.0% during the fourth quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 452 shares during the last quarter. We Are One Seven LLC acquired a new stake in shares of Baxter International during the fourth quarter worth $34,000. Finally, Financial Gravity Companies Inc. acquired a new stake in shares of Baxter International during the fourth quarter worth $45,000. 81.39% of the stock is owned by hedge funds and other institutional investors.
NYSE:BAX opened at $76.94 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.50 and a current ratio of 2.09. Baxter International Inc has a 12 month low of $61.05 and a 12 month high of $78.38. The stock has a market capitalization of $39.43 billion, a price-to-earnings ratio of 25.23, a P/E/G ratio of 1.90 and a beta of 1.00.
Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, January 31st. The medical instruments supplier reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. The company had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.80 billion. Equities research analysts anticipate that Baxter International Inc will post 3.27 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 1st. Shareholders of record on Friday, March 1st will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.99%. The ex-dividend date is Thursday, February 28th. Baxter International’s dividend payout ratio (DPR) is presently 24.92%.
In other Baxter International news, SVP Jeanne K. Mason sold 37,274 shares of the firm’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $72.00, for a total value of $2,683,728.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Thomas T. Stallkamp sold 3,187 shares of the firm’s stock in a transaction dated Friday, January 18th. The shares were sold at an average price of $70.00, for a total value of $223,090.00. Following the completion of the transaction, the director now directly owns 9,418 shares in the company, valued at $659,260. The disclosure for this sale can be found here. Insiders sold 44,599 shares of company stock worth $3,216,661 over the last three months. 0.07% of the stock is currently owned by corporate insiders.
Several brokerages recently weighed in on BAX. Zacks Investment Research lowered Baxter International from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Citigroup raised Baxter International from a “neutral” rating to a “buy” rating and increased their target price for the stock from $69.00 to $76.00 in a research report on Wednesday, January 2nd. Credit Suisse Group began coverage on Baxter International in a research report on Monday, December 17th. They issued an “outperform” rating and a $77.00 target price on the stock. Barclays raised Baxter International from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $67.00 to $72.00 in a research report on Friday, February 1st. Finally, UBS Group began coverage on Baxter International in a research report on Tuesday, November 27th. They issued a “buy” rating and a $80.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $76.56.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.